Duarte, CANCT07432295Now EnrollingIRB Ready

Solid Tumor Clinical Trial in Duarte, CA

Access cutting-edge solid tumor treatment through this clinical trial at a research site in Duarte. Study-provided care at no cost to qualified participants.

Sponsored by I-Mab Biopharma US Limited

Quick Self-Assessment

See if you qualify for this Duarte location

Preparing your pre-screening questions…

Expert Care in Duarte

Access solid tumor specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related solid tumor treatment provided free

Apply for This Duarte Location

Check if you qualify for this solid tumor clinical trial in Duarte, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Duarte

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Duarte site if eligible
  4. 4Begin participation

About This Solid Tumor Study in Duarte

The goal of this clinical trial is to learn if givastomig in combination with standard therapy works to treat adults with cancer in the stomach and/or esophagus (GEA adenocarcinoma). It will also help the researchers to learn more about the safety of givastomig. The main questions it aims to answer are: * Does the addition of givastomig to standard therapy increase the amount of time that participants survive without progression of their cancer? * What toxicities do participants experience when taking givastomig? Participants may be able to take part in the study if they have unresectable or metastatic GEA and if their cancer cells express certain proteins called Claudin 18.2 (CLDN18.2) and PD-L1. Participants whose cancer cells express a protein called HER2 cannot take part. Up to 180 participants will be randomly assigned to received givastomig at one of two doses in combination with an immunotherapy medicine called nivolumab and chemotherapy OR to receive nivolumab and chemotherapy alone. These therapies will be given primarily via intravenous (into a vein) infusion every 2 or 3 weeks. Participants will: * Visit the study treatment center for infusions and/or check-ups and tests every 1-3 weeks * Report any changes in their symptoms to their study doctors * Have scans to check for any changes in their cancer every 8-12 weeks

Sponsor: I-Mab Biopharma US Limited

Who Can Participate

Inclusion Criteria

Histologically confirmed unresectable, locally advanced, or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma (EAC).
Treatment-naïve for advanced/metastatic disease (prior adjuvant/neoadjuvant therapy allowed if ≥6 months since last dose).
CLDN18.2 positive (membrane intensity score ≥1+ on ≥1% of tumor cells).
PD-L1 positive (CPS ≥1).
At least 1 measurable lesion per RECIST v1.1.
ECOG performance status 0 or 1.
Adequate organ function, including:
Hematologic: WBC ≥2,000/μL; ANC ≥1,500/μL; platelets ≥100,000/μL; hemoglobin ≥9 g/dL
Hepatic: AST/ALT ≤3×ULN (≤5×ULN if liver metastases); bilirubin ≤1.5×ULN (≤3×ULN if Gilbert's)
Renal: Creatinine ≤1.5×ULN or eGFR ≥50 mL/min/1.73 m²
Life expectancy ≥90 days.
Women of childbearing potential (WOCBP) and men must use effective contraception during the study and for a defined period after treatment.
Willing and able to provide informed consent and comply with study procedures

Exclusion Criteria

HER2-positive tumors.
Second malignancy within 3 years, except certain skin or cervical cancers.
Active or unstable gastrointestinal ulcer or bleeding within 6 weeks.
Active autoimmune disease requiring systemic therapy within past 2 years or ongoing immunosuppressive therapy.
Active pneumonitis or history requiring steroids/immunosuppressive therapy within 3 years.
Participation in another therapeutic clinical trial.
Major surgery or significant injury within 4 weeks prior to first dose, or planned major surgery within 6 months.
Radiotherapy within protocol-specified timeframes without adequate recovery.
Active CNS metastases or carcinomatous meningitis (previously treated brain metastases allowed if stable).
Significant cardiovascular disease (NYHA Class 3-4 CHF, recent MI, unstable angina, TIA/stroke, or major cardiac procedures within 6 months).
Active or uncontrolled HIV, hepatitis B, or hepatitis C infection, or immunodeficiency (controlled infection allowed).
Receipt of live vaccine within 30 days or other vaccines within 7 days of first dose.
Active infection requiring parenteral therapy.
Known hypersensitivity to study drug components (e.g., DPD deficiency).
Any other condition or laboratory abnormality that, in the investigator's judgment, increases risk or interferes with study participation.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Duarte?

Yes, this clinical trial (NCT07432295) has an active research site in Duarte, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Solid Tumor Treatment Options in Duarte, CA

If you're searching for solid tumor treatment options in Duarte, CA, this clinical trial (NCT07432295) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Duarte research site is actively enrolling participants for this clinical trial. You'll receive care from experienced solid tumor specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all solid tumor clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in Duarte, CA

See all advanced solid tumors clinical trials recruiting in Duarte — not just this study.

Browse Advanced Solid Tumors Trials in Duarte →

Browse More Trials by Condition

Advanced Solid Tumors TrialsAll Conditions →

Ready to Join in Duarte?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Duarte, CA